A phase 3 trial led by MSK’s Dr. Lorenzo Falchi found that adding #epcoritamab to #rituximab + #lenalidomide significantly improves outcomes for people with follicular lymphoma. Epcoritamab received FDA approval based on these findings. #ASH25
Learn more: www.mskcc.org/news/new-tri...
Learn more: www.mskcc.org/news/new-tri...
December 7, 2025 at 4:53 PM
A phase 3 trial led by MSK’s Dr. Lorenzo Falchi found that adding #epcoritamab to #rituximab + #lenalidomide significantly improves outcomes for people with follicular lymphoma. Epcoritamab received FDA approval based on these findings. #ASH25
Learn more: www.mskcc.org/news/new-tri...
Learn more: www.mskcc.org/news/new-tri...
“These findings compare favorably with R-CHOP alone and support the ongoing phase 3 trial of epcoritamab + R-CHOP in 1L DLBCL.”
MSK lymphoma specialist Dr. Lorenzo Falchi shared new research today at @ash-hematology.bsky.social.
#ASH24
Learn more:
bit.ly/4goJHaK
MSK lymphoma specialist Dr. Lorenzo Falchi shared new research today at @ash-hematology.bsky.social.
#ASH24
Learn more:
bit.ly/4goJHaK
December 8, 2024 at 11:43 PM
“These findings compare favorably with R-CHOP alone and support the ongoing phase 3 trial of epcoritamab + R-CHOP in 1L DLBCL.”
MSK lymphoma specialist Dr. Lorenzo Falchi shared new research today at @ash-hematology.bsky.social.
#ASH24
Learn more:
bit.ly/4goJHaK
MSK lymphoma specialist Dr. Lorenzo Falchi shared new research today at @ash-hematology.bsky.social.
#ASH24
Learn more:
bit.ly/4goJHaK
Good news for patients with #DLBCL Diffuse large B-cell #lymphoma that #epcoritamab has received a positive funding recommendation from the PBAC in Australia. #lymsm 2L Axi-Cel this week, bispecifics in the 3L soon, it seems. Good news on a Friday. #lymsm
Pharmaceutical Benefits Scheme (PBS) | PBAC Outcomes
See also
buff.ly
December 20, 2024 at 6:42 AM
Good news for patients with #DLBCL Diffuse large B-cell #lymphoma that #epcoritamab has received a positive funding recommendation from the PBAC in Australia. #lymsm 2L Axi-Cel this week, bispecifics in the 3L soon, it seems. Good news on a Friday. #lymsm
Congratulations to Dr. Lorenzo Falchi of @mskcancercenter.bsky.social on the FDA approval of epcoritamab-bysp with lenalidomide and rituximab for adults with relapsed or refractory follicular #lymphoma! A huge win for those with the condition. Dr. Falchi will present phase 3 trial data at #ASH25.
The @fda.gov approved the immunotherapy epcoritamab-bysp with lenalidomide and rituximab for relapsed or refractory follicular lymphoma: buff.ly/JNJZKMb
FDA approves epcoritamab-bysp for follicular lymphoma indications
FDA approves epcoritamab-bysp for follicular lymphoma indications
www.fda.gov
November 18, 2025 at 7:14 PM
Congratulations to Dr. Lorenzo Falchi of @mskcancercenter.bsky.social on the FDA approval of epcoritamab-bysp with lenalidomide and rituximab for adults with relapsed or refractory follicular #lymphoma! A huge win for those with the condition. Dr. Falchi will present phase 3 trial data at #ASH25.
For patients with aggressive lymphoma (DLBCL) whose cancer returns, new options are vital. A Phase 3 trial shows epcoritamab + lenalidomide reduced progression/death risk by 60% vs. chemo. It's promising to see chemotherapy-free combos improve outcomes.
AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Relapsed or Refractor
A Phase 3 clinical trial has shown that a new chemotherapy-free combination treatment, epcoritamab plus lenalidomide, significantly improves outcomes for adult patients with an aggressive blood cancer
www.biospace.com
June 30, 2026 at 8:04 PM
For patients with aggressive lymphoma (DLBCL) whose cancer returns, new options are vital. A Phase 3 trial shows epcoritamab + lenalidomide reduced progression/death risk by 60% vs. chemo. It's promising to see chemotherapy-free combos improve outcomes.
Early results from Epcore NHL-2 Arm 3 show promise for fixed-duration epcoritamab with bendamustine + rituximab as a first-line treatment for follicular lymphoma - Joshua Brody MD 🎥🩸 #ASH24
👉 www.vjhemonc.com/event/ash-20...
@ash-hematology.bsky.social
👉 www.vjhemonc.com/event/ash-20...
@ash-hematology.bsky.social
December 9, 2024 at 6:05 PM
Early results from Epcore NHL-2 Arm 3 show promise for fixed-duration epcoritamab with bendamustine + rituximab as a first-line treatment for follicular lymphoma - Joshua Brody MD 🎥🩸 #ASH24
👉 www.vjhemonc.com/event/ash-20...
@ash-hematology.bsky.social
👉 www.vjhemonc.com/event/ash-20...
@ash-hematology.bsky.social
The @fda.gov approved the immunotherapy epcoritamab-bysp with lenalidomide and rituximab for relapsed or refractory follicular lymphoma: buff.ly/JNJZKMb
FDA approves epcoritamab-bysp for follicular lymphoma indications
FDA approves epcoritamab-bysp for follicular lymphoma indications
www.fda.gov
November 18, 2025 at 5:43 PM
The @fda.gov approved the immunotherapy epcoritamab-bysp with lenalidomide and rituximab for relapsed or refractory follicular lymphoma: buff.ly/JNJZKMb
Epcoritamab Monotherapy Induces Complete Responses in R/R CLL @ash-hematology.bsky.social #ASH24 #lymsm #hematology
www.onclive.com/view/epcorit...
www.onclive.com/view/epcorit...
Epcoritamab Monotherapy Induces Complete Responses in R/R CLL
Single-agent, subcutaneous epcoritamab generated deep responses in patients with relapsed/refractory chronic lymphocytic leukemia.
www.onclive.com
December 8, 2024 at 9:08 PM
Epcoritamab Monotherapy Induces Complete Responses in R/R CLL @ash-hematology.bsky.social #ASH24 #lymsm #hematology
www.onclive.com/view/epcorit...
www.onclive.com/view/epcorit...
Epcoritamab Integrated Upfront into Salvage Therapy in R/R DLBCL - Yan Leyfman
@yleyfman.bsky.social
oncodaily.com/voices/yan-l...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
@yleyfman.bsky.social
oncodaily.com/voices/yan-l...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Yan Leyfman: Epcoritamab Integrated Upfront into Salvage Therapy in R/R DLBCL - OncoDaily
Yan Leyfman: Epcoritamab Integrated Upfront into Salvage Therapy in R/R DLBCL / cancer, Chan Y. Cheah, Daniel Morillo, David Lewis, Fritz Offner, Gerardo
oncodaily.com
April 6, 2026 at 6:32 PM
Epcoritamab Integrated Upfront into Salvage Therapy in R/R DLBCL - Yan Leyfman
@yleyfman.bsky.social
oncodaily.com/voices/yan-l...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
@yleyfman.bsky.social
oncodaily.com/voices/yan-l...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
At #ASH24, join Dr. Lorenzo Falchi to learn about the Epcore NHL-2 long-term follow-up trial results of epcoritamab + R-CHOP for patients with previously untreated diffuse large B-cell lymphoma with high-risk features.
1 p.m. PST @mskcancercenter.bsky.social
https://buff.ly/4f6h0OH
1 p.m. PST @mskcancercenter.bsky.social
https://buff.ly/4f6h0OH
December 8, 2024 at 7:00 PM
At #ASH24, join Dr. Lorenzo Falchi to learn about the Epcore NHL-2 long-term follow-up trial results of epcoritamab + R-CHOP for patients with previously untreated diffuse large B-cell lymphoma with high-risk features.
1 p.m. PST @mskcancercenter.bsky.social
https://buff.ly/4f6h0OH
1 p.m. PST @mskcancercenter.bsky.social
https://buff.ly/4f6h0OH
Fixed-Duration Epcoritamab Is Active, Safe in Older Newly Diagnosed LBCL @ash-hematology.bsky.social
#ASH24 #lymsm #oncology www.onclive.com/view/fixed-d...
#ASH24 #lymsm #oncology www.onclive.com/view/fixed-d...
Fixed-Duration Epcoritamab Is Active, Safe in Older Newly Diagnosed LBCL
Epcoritamab produced responses in older patients with newly diagnosed large B-cell lymphoma.
www.onclive.com
December 10, 2024 at 7:54 PM
Fixed-Duration Epcoritamab Is Active, Safe in Older Newly Diagnosed LBCL @ash-hematology.bsky.social
#ASH24 #lymsm #oncology www.onclive.com/view/fixed-d...
#ASH24 #lymsm #oncology www.onclive.com/view/fixed-d...
Epcoritamab plus rituximab-lenalidomide shows high activity in first-line follicular lymphoma
Early-phase / non-randomised trial · Phase 1/2 · Oncology · Lancet Haematology · 2026-09-01
Authors report: Epcoritamab plus…
ENCLAI Daily → enclai.net/news
#ClinicalResearch #Pharma #MedSky #Oncology
Early-phase / non-randomised trial · Phase 1/2 · Oncology · Lancet Haematology · 2026-09-01
Authors report: Epcoritamab plus…
ENCLAI Daily → enclai.net/news
#ClinicalResearch #Pharma #MedSky #Oncology
September 4, 2026 at 4:45 AM
Epcoritamab plus rituximab-lenalidomide shows high activity in first-line follicular lymphoma
Early-phase / non-randomised trial · Phase 1/2 · Oncology · Lancet Haematology · 2026-09-01
Authors report: Epcoritamab plus…
ENCLAI Daily → enclai.net/news
#ClinicalResearch #Pharma #MedSky #Oncology
Early-phase / non-randomised trial · Phase 1/2 · Oncology · Lancet Haematology · 2026-09-01
Authors report: Epcoritamab plus…
ENCLAI Daily → enclai.net/news
#ClinicalResearch #Pharma #MedSky #Oncology
Epcoritamab Elicits Durable CR Rates, Increases MRD Negativity in Relapsed/Refractory DLBCL @unmc.bsky.social #lymsm #oncology
Read more: www.onclive.com/view/epcorit...
Read more: www.onclive.com/view/epcorit...
Epcoritamab Elicits Durable CR Rates, Increases MRD Negativity in Relapsed/Refractory DLBCL
Julie M. Vose, MD, MBA, discusses the 3-year follow-up data with epcoritamab in patients with relapsed/refractory diffuse large B-cell lymphoma.
www.onclive.com
February 20, 2025 at 7:35 PM
Epcoritamab Elicits Durable CR Rates, Increases MRD Negativity in Relapsed/Refractory DLBCL @unmc.bsky.social #lymsm #oncology
Read more: www.onclive.com/view/epcorit...
Read more: www.onclive.com/view/epcorit...
🏥 New from #ASCO26: Real-world data for Mosunetuzumab & Epcoritamab in #follicularlymphoma shows a 72% CR rate—even in heavily pretreated and elderly patients!
Better yet: ZERO high-grade CRS cases reported. 🧬
Full story: https://bit.ly/4u8JoY6
#Lymphoma #ASCO2026
Better yet: ZERO high-grade CRS cases reported. 🧬
Full story: https://bit.ly/4u8JoY6
#Lymphoma #ASCO2026
Real-World Outcomes for Mosunetuzumab, Epcoritamab Similar to Trial Findings in rrFL
Mosunetuzumab and epcoritamab demonstrated response rates and survival outcomes comparable to clinical trial findings in a real-world setting.
bit.ly
May 30, 2026 at 5:25 PM
🏥 New from #ASCO26: Real-world data for Mosunetuzumab & Epcoritamab in #follicularlymphoma shows a 72% CR rate—even in heavily pretreated and elderly patients!
Better yet: ZERO high-grade CRS cases reported. 🧬
Full story: https://bit.ly/4u8JoY6
#Lymphoma #ASCO2026
Better yet: ZERO high-grade CRS cases reported. 🧬
Full story: https://bit.ly/4u8JoY6
#Lymphoma #ASCO2026
Epcoritamab Plus Rituximab and Lenalidomide Improves PFS in Pretreated Follicular Lymphoma @ash.hematology.org @mskcancercenter.bsky.social #ASH25 www.onclive.com/view/epcorit...
Epcoritamab Plus Rituximab and Lenalidomide Improves PFS in Pretreated Follicular Lymphoma | OncLive
The addition of epcoritamab to lenalidomide and rituximab improved PFS and ORR vs the combination alone in relapsed/refractory follicular lymphoma.
www.onclive.com
December 7, 2025 at 4:34 PM
Epcoritamab Plus Rituximab and Lenalidomide Improves PFS in Pretreated Follicular Lymphoma @ash.hematology.org @mskcancercenter.bsky.social #ASH25 www.onclive.com/view/epcorit...
Epcoritamab Plus R-ICE Yields High CR Rates and Improves Transplant Eligibility in R/R DLBCL #EHA2025 #lymsm #oncology www.onclive.com/view/epcorit...
Epcoritamab Plus R-ICE Yields High CR Rates and Improves Transplant Eligibility in R/R DLBCL
The majority of transplant-eligible patients with relapsed/refractory DLBCL completed treatment with epcoritamab plus R-ICE and proceeded to ASCT.
www.onclive.com
June 15, 2025 at 5:55 PM
Epcoritamab Plus R-ICE Yields High CR Rates and Improves Transplant Eligibility in R/R DLBCL #EHA2025 #lymsm #oncology www.onclive.com/view/epcorit...
#ABBV AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
https://www.stocktitan.net/news/ABBV/abb-vie-announces-positive-phase-3-results-for-epcoritamab-plus-32ufd37lufz6.html
https://www.stocktitan.net/news/ABBV/abb-vie-announces-positive-phase-3-results-for-epcoritamab-plus-32ufd37lufz6.html
AbbVie lymphoma trial cuts progression risk 60% in Phase 3 test
Epcoritamab plus lenalidomide beat R-GemOx in relapsed or refractory DLBCL, with 60% lower risk of progression or death in U.S. analysis.
www.stocktitan.net
June 29, 2026 at 8:15 PM
#ABBV AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
https://www.stocktitan.net/news/ABBV/abb-vie-announces-positive-phase-3-results-for-epcoritamab-plus-32ufd37lufz6.html
https://www.stocktitan.net/news/ABBV/abb-vie-announces-positive-phase-3-results-for-epcoritamab-plus-32ufd37lufz6.html
Investigational Epcoritamab (DuoBody ® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB): Results show 96 percent overall response…
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB): Results show 96 percent overall response…
Investigational Epcoritamab (DuoBody ® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB): Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and 80 percent 21-month progression-free survival (PFS) in patients with relapsed or refractory (R/R) follicular lymphoma (FL) following treatment with epcoritamab plus lenalidomide + rituximab (R2) Long-term follow-up results demonstrated strong and durable efficacy, with an estimated two-year overall survival (OS) rate of 90 percent…
geniousgrow.online
December 8, 2024 at 12:39 AM
Investigational Epcoritamab (DuoBody ® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB): Results show 96 percent overall response…
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB): Results show 96 percent overall response…
🚨The latest Phase 3 Trial Update!
▪️ AbbVie reports topline Phase 3 EPCORE® DLBCL-1 results for epcoritamab in R/R DLBCL, advancing evidence for CD3xCD20 bispecific therapy.
▪️ Subcutaneous epcoritamab improved PFS vs chemoimmunotherapy (HR 0.74), with higher complete responses.
▪️ AbbVie reports topline Phase 3 EPCORE® DLBCL-1 results for epcoritamab in R/R DLBCL, advancing evidence for CD3xCD20 bispecific therapy.
▪️ Subcutaneous epcoritamab improved PFS vs chemoimmunotherapy (HR 0.74), with higher complete responses.
January 19, 2026 at 9:30 AM
🚨The latest Phase 3 Trial Update!
▪️ AbbVie reports topline Phase 3 EPCORE® DLBCL-1 results for epcoritamab in R/R DLBCL, advancing evidence for CD3xCD20 bispecific therapy.
▪️ Subcutaneous epcoritamab improved PFS vs chemoimmunotherapy (HR 0.74), with higher complete responses.
▪️ AbbVie reports topline Phase 3 EPCORE® DLBCL-1 results for epcoritamab in R/R DLBCL, advancing evidence for CD3xCD20 bispecific therapy.
▪️ Subcutaneous epcoritamab improved PFS vs chemoimmunotherapy (HR 0.74), with higher complete responses.
The European Commission has approved #epcoritamab in combination with lenalidomide and rituximab for adults with relapsed/refractory #FollicularLymphoma after at least one prior line of therapy.
💡Epcoritamab is a CD3×CD20 bispecific antibody that redirects T cells to eliminate malignant B cells
💡Epcoritamab is a CD3×CD20 bispecific antibody that redirects T cells to eliminate malignant B cells
July 7, 2026 at 4:02 PM
The European Commission has approved #epcoritamab in combination with lenalidomide and rituximab for adults with relapsed/refractory #FollicularLymphoma after at least one prior line of therapy.
💡Epcoritamab is a CD3×CD20 bispecific antibody that redirects T cells to eliminate malignant B cells
💡Epcoritamab is a CD3×CD20 bispecific antibody that redirects T cells to eliminate malignant B cells
Epcoritamab also showed clinically relevant, numerically higher ORRs and improved safety vs mosunetuzumab or odronextamab. buff.ly/e3qt3Tp #hemesky
August 15, 2025 at 3:03 PM
Epcoritamab also showed clinically relevant, numerically higher ORRs and improved safety vs mosunetuzumab or odronextamab. buff.ly/e3qt3Tp #hemesky
At #EHA2026, Prof Umberto Vitolo discusses updated EPCORE DLBCL-3 results showing fixed-duration epcoritamab achieved a 73% ORR and 63% CR rate in frail, elderly patients with newly diagnosed DLBCL. Watch his interview👉https://bit.ly/4wzkKko #DLBCL #Haematology
Epcoritamab induces deep and durable responses in chemotherapy-ineligible elderly patients with diffuse large B-cell lymphoma - ecancer
Prof Umberto Vitolo speaks to ecancer about the updated results from the phase 2 EPCORE DLBCL-3 trial evaluating fixed-duration epcoritamab monotherapy, a CD3&t
bit.ly
August 19, 2026 at 8:22 AM
At #EHA2026, Prof Umberto Vitolo discusses updated EPCORE DLBCL-3 results showing fixed-duration epcoritamab achieved a 73% ORR and 63% CR rate in frail, elderly patients with newly diagnosed DLBCL. Watch his interview👉https://bit.ly/4wzkKko #DLBCL #Haematology